CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

← Liquidia Corporation (LQDA) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫

Liquidia Corporation (LQDA)

Pharmaceutical Preparations · market cap $6.1B · as of 2026-07-12

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst
None scheduled
Pipeline
4
programs
Upcoming events
0
next 90d+
Dossier
Ready
cached
Liquidia Corporation (LQDA) is a ~170-person specialty pharma company with a market cap of ~$6.9B focused on pulmonary hypertension. Its lead asset LIQ861 (inhaled treprostinil) is in Phase 3 for primary pulmonary hypertension, with a PDUFA date that passed June 27, 2026 with an unknown outcome per the provided facts. A second Phase 3 asset, L606, targets pulmonary hypertension due to lung disease.
The catalyst path

No upcoming catalysts in our calendar.

Pipeline
AssetPhaseIndication
LIQ861 Inhaled TreprostinilPhase 3Primary Pulmonary Hypertension
Fluzone® (2010/2011 Inactivated Trivalent Influenza Vaccine)Phase 2Influenza
L606Phase 3Pulmonary Hypertension Due to Lung Disease (Disorder)
LIQ001Phase 2Influenza
Price & technical context
3-month
-17.5%
6-month
-8.6%
12-month
+87.5%
52-wk range
$25.91–$91.03
vs 50-day MA
+17.9%
vs 200-day MA
+3.0%
Realized vol
110.4%
Max drawdown
-71.5%

Daily closes through 2026-11-19. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

Sources & data
  • SEC filings — EDGAR filings for LQDA (10-K, 10-Q, S-3, 13D/G, Form 4)
  • Clinical trials — 4 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
  • Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
  • Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.